Post-trial follow-up of the AT CASH EPOC trial (65 of 80 patients with cerebral cavernous malformations): symptomatic haemorrhage recurred in 4 after stopping atorvastatin vs 1 after stopping placebo (HR 0.162, placebo vs atorvastatin); hypothesis-generating.
RCTn = 65
Ali et al. Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo